Jeremy Blavier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jeremy Blavier has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Claude Twizere
Laboratory of Viral Interactomes, GIGA Institute, University of Liege, Liege, Belgium
2 shared publications - Julien Olivet
Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute (DFCI), 450 Brookline Avenue, Boston, MA, 02215, USA
2 shared publications - Sibusiso B. Maseko
Laboratory of Viral Interactomes, Unit of Molecular Biology of Diseases, GIGA Institute University of Liege Liège Belgium
2 shared publications - Adrià Sogues
Structural and Molecular Microbiology, VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium
1 shared publication - Alexander N. Volkov
VIB-VUB Center for Structural Biology, Vlaams Instituut voor Biotechnologie (VIB), Brussels, Belgium
1 shared publication Ali Bazarbachi
Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
1 shared publication
Latest Publications
- Open Access
- 11 March 2024
- Published by Springer Nature in Molecular Systems Biology
- Vol. 20 (4) , 428-457
AI-guided pipeline for protein–protein interaction drug discovery identifies a SARS-CoV-2 inhibitor
Protein–protein interactions (PPIs) offer great opportunities to expand the druggable proteome and therapeutically tackle various diseases, but remain challenging targets for drug discovery. Here, we provide a comprehensive pipeline that combines experimental and computational tools to identify and validate PPI targets and perform early-stage drug discovery. We have developed a machine learning approach that prioritizes interactions by analyzing quantitative data from binary PPI assays or AlphaFold-Multimer predictions. Using the quantitative assay LuTHy together with our machine learning algorithm, we identified high-confidence interactions among SARS-CoV-2 proteins for which we predicted three-dimensional structures using AlphaFold-Multimer. We employed VirtualFlow to target the contact interface of the NSP10-NSP16 SARS-CoV-2 methyltransferase complex by ultra-large virtual drug screening. Thereby, we identified a compound that binds to NSP10 and inhibits its interaction with NSP16, while also disrupting the methyltransferase activity of the complex, and SARS-CoV-2 replication. Overall, this pipeline will help to prioritize PPI targets to accelerate the discovery of early-stage drug candidates targeting protein complexes and pathways.
- 11 March 2024
- Published by Springer Nature in Molecular Systems Biology
- Vol. 20 (4) , 428-457
Open AccessAI-guided pipeline for protein–protein interaction drug discovery identifies a SARS-CoV-2 inhibitor
Protein–protein interactions (PPIs) offer great opportunities to expand the druggable proteome and therapeutically tackle various diseases, but remain challenging targets for drug discovery. Here, we provide a comprehensive pipeline that combines experimental and computational tools to identify and validate PPI targets and perform early-stage drug discovery. We have developed a machine learning approach that prioritizes interactions by analyzing quantitative data from binary PPI assays or AlphaFold-Multimer predictions. Using the quantitative assay LuTHy together with our machine learning algorithm, we identified high-confidence interactions among SARS-CoV-2 proteins for which we predicted three-dimensional structures using AlphaFold-Multimer. We employed VirtualFlow to target the contact interface of the NSP10-NSP16 SARS-CoV-2 methyltransferase complex by ultra-large virtual drug screening. Thereby, we identified a compound that binds to NSP10 and inhibits its interaction with NSP16, while also disrupting the methyltransferase activity of the complex, and SARS-CoV-2 replication. Overall, this pipeline will help to prioritize PPI targets to accelerate the discovery of early-stage drug candidates targeting protein complexes and pathways.
- 20 July 2023
- Published by Elsevier in Antiviral Research
- Vol. 217, 105675
Identification of small molecule antivirals against HTLV-1 by targeting the hDLG1-Tax-1 protein-protein interaction
- 20 July 2023
- Published by Elsevier in Antiviral Research
- Vol. 217, 105675
Identification of small molecule antivirals against HTLV-1 by targeting the hDLG1-Tax-1 protein-protein interaction
- 1 December 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 225, 113777
Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27
- 1 December 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 225, 113777
Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27